RT Journal Article
SR Electronic
T1 Immunogenic profile of SARS-CoV-2 spike in individuals recovered from COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.17.20104869
DO 10.1101/2020.05.17.20104869
A1 Jennifer A Juno
A1 Hyon-Xhi Tan
A1 Wen Shi Lee
A1 Arnold Reynaldi
A1 Hannah G Kelly
A1 Kathleen Wragg
A1 Robyn Esterbauer
A1 Helen E Kent
A1 C Jane Batten
A1 Francesca L Mordant
A1 Nicholas A Gherardin
A1 Phillip Pymm
A1 Melanie H Dietrich
A1 Nichollas E Scott
A1 Wai-Hong Tham
A1 Dale I Godfrey
A1 Kanta Subbarao
A1 Miles P Davenport
A1 Stephen J Kent
A1 Adam K Wheatley
YR 2020
UL http://medrxiv.org/content/early/2020/05/21/2020.05.17.20104869.abstract
AB The rapid global spread of SARS-CoV-2 and resultant mortality and social disruption have highlighted the need to better understand coronavirus immunity to expedite vaccine development efforts. Multiple candidate vaccines, designed to elicit protective neutralising antibodies targeting the viral spike glycoprotein, are rapidly advancing to clinical trial. However, the immunogenic properties of the spike protein in humans are unresolved. To address this, we undertook an in-depth characterisation of humoral and cellular immunity against SARS-CoV-2 spike in humans following mild to moderate SARS-CoV-2 infection. We find serological antibody responses against spike are routinely elicited by infection and correlate with plasma neutralising activity and capacity to block ACE2/RBD interaction. Expanded populations of spike-specific memory B cells and circulating T follicular helper cells (cTFH) were detected within convalescent donors, while responses to the receptor binding domain (RBD) constitute a minor fraction. Using regression analysis, we find high plasma neutralisation activity was associated with increased spike-specific antibody, but notably also with the relative distribution of spike-specific cTFH subsets. Thus both qualitative and quantitative features of B and T cell immunity to spike constitute informative biomarkers of the protective potential of novel SARS-CoV-2 vaccines.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology (SJK), an NHMRC program grant APP1149990 (SJK), NHMRC project grant GNT1162760 (AKW), and the Jack Ma Foundation (DIG, 489NAG). WHT is a Howard Hughes Medical Institute-Wellcome Trust International Research Scholar (208693/Z/17/Z).JAJ, DIG, MPD,WHT, SJK and AKW are supported by NHMRC fellowships.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available from the authors upon reasonable request